Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Tea Pemovska, PhD, Johannes Bigenzahn, MD PhD, Ismet Srndic, MSc, Alexander Lercher, MSc, Andreas Bergthaler, PhD, Adrian Cesar Razquin, PhD, Felix Kartnig, MD, Philipp B. Staber, MD PhD, Giulio Superti Furga, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134769

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

SLC20A1 at the Interface between Macrophages and Red Blood Cells

Federica Quattrone, MSc, Riem Gawish, PhD, Rui Martins, PhD, Anna-Dorothea Gorki, PhD, Martin Watzenboeck, MD, Anastasiya Hladik, Karin Lakovits, Manuele Rebsamen, PhD, Enrico Girardi, PhD, Giulio Superti-Furga, PhD, Sylvia Knapp, MD PhD

Blood (2019) 134 (Supplement_1): 428.

https://doi.org/10.1182/blood-2019-123758

Published: 2019

Journal Articles

Unbiased Profiling of the Immunomodulatory Properties of Soluble Proteins

Nikolaus Krall, PhD, Gregory Ian Vladimer, PhD, Berend Snijder, PhD, Noemi Meszaros, Nicole Müller-Sienerth, PhD, Gavin Wright, Giulio Superti-Furga, PhD

Blood (2017) 130 (Supplement 1): 2293.

https://doi.org/10.1182/blood.V130.Suppl_1.2293.2293

Published: 2017

Journal Articles

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 855.

https://doi.org/10.1182/blood.V130.Suppl_1.855.855

Published: 2017

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Blood (2017) 130 (Supplement 1): 800.

https://doi.org/10.1182/blood.V130.Suppl_1.800.800

Published: 2017

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Blood (2013) 122 (21): 439.

https://doi.org/10.1182/blood.V122.21.439.439

Published: 2013

Journal Articles

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Blood (2013) 122 (21): 267.

https://doi.org/10.1182/blood.V122.21.267.267

Published: 2013

Journal Articles

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Hadzijusufovic Emir, DVM, Karin Albrecht-Schgoer, PhD, Kilian Huber, PhD, Florian Grebien, PhD, Gregor Eisenwort, MD, PhD, Wilfried Schgoer, MD, PhD, Christoph Kaun, Susanne Herndlhofer, Markus Theurl, PhD, Sabine Cerny-Reiterer, D.V.M., Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Rix Uwe, PhD, Johann Wojta, PhD, Dominik Wolf, MD, Giulio Superti-Furga, PhD, Rudolf Kirchmair, MD, Peter Valent

Blood (2013) 122 (21): 257.

https://doi.org/10.1182/blood.V122.21.257.257

Published: 2013

Journal Articles

Bcr-Abl Directly Activates Stat5 Independent of Jak2

Oliver D. Hantschel, MSc, PhD, Eva Eckelhart, MSc, Ines Kaupe, MSc, Florian Grebien, MSc, PhD, Kay-Uwe Wagner, PhD, Veronika Sexl, MD, Giulio Superti-Furga, PhD

Blood (2010) 116 (21): 511.

https://doi.org/10.1182/blood.V116.21.511.511

Published: 2010

Journal Articles

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

Oliver Hantschel, PhD, Uwe Rix, PhD, Tilmann Buerckstuemmer, PhD, Uwe Schmidt, PhD, Michael Kneidinger, MD, Keiryn L. Bennett, PhD, Ines Kaupe, BSc, Wilfried Ellmeier, PhD, Peter Valent, MD, Giulio Superti-Furga, PhD

Blood (2007) 110 (11): 4542.

https://doi.org/10.1182/blood.V110.11.4542.4542

Published: 2007

Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 2936.

https://doi.org/10.1182/blood.V110.11.2936.2936

Published: 2007

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

Daniel W. Sherbenou, BA, Oliver Hantschel, PhD, Stephanie Willis, BS, Richard D. Press, MD, Brian J. Druker, MD, Giulio Superti-Furga, PhD, Michael W. Deininger, MD, PhD

Blood (2006) 108 (11): 2188.

https://doi.org/10.1182/blood.V108.11.2188.2188

Published: 2006

NARROW

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

SLC20A1 at the Interface between Macrophages and Red Blood Cells

Unbiased Profiling of the Immunomodulatory Properties of Soluble Proteins

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis

Germline RBBP6 Mutations In Myeloproliferative Neoplasms

Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML

Bcr-Abl Directly Activates Stat5 Independent of Jak2

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only